Serena Merante

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR -positive hypereosinophilic syndrome. Results of a multicenter prospective study

Michele Baccarani, Daniela Cilloni, Michela Rondoni et al. · Haematologica · 2007 · 195 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Simona Soverini, Alessandra Gnani, Sabrina Colarossi et al. · Blood · 2009 · 174 citations · Full text

Medicine, Genetics, Oncology +16

International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study

Wolfgang R. Sperr, Michael Kundi, Iván Álvarez‐Twöse et al. · The Lancet Haematology · 2019 · 138 citations · Full text

Life Sciences, Health Sciences, Diagnostic Pathology +6

Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.

Serena Merante, Ester Orlandi, Paolo Bernasconi et al. · PubMed · 2005 · 106 citations

Medicine, Hematology, Pharmacotherapy +11

Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients

Ilaria Iacobucci, Giuseppe Saglio, Gianantonio Rosti et al. · Clinical Cancer Research · 2006 · 95 citations · Full text

Life Sciences, Hematology, Oncology +13